Last reviewed · How we verify
Faslodex
At a glance
| Generic name | Faslodex |
|---|---|
| Also known as | Fulvestrant |
| Sponsor | Translational Oncology Research International |
| Target | NAD-dependent protein deacylase sirtuin-5, mitochondrial, Bifunctional epoxide hydrolase 2, G-protein coupled estrogen receptor 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Metastatic Breast Cancer Progression Post-Antiestrogen Therapy
Common side effects
- Arthralgia
- Injection Site Pain
- Nausea
- Back Pain
- Hot Flash
- Fatigue
- Bone Pain
- Headache
- Myalgia
- Pain in Extremity
- Vomiting
- Asthenia
Serious adverse events
- Drug Hypersensitivity
- Injection Site Hypersensitivity
- Elevated Liver Enzymes
- Grade 3-4 Alanine Aminotransferase Increased
- Grade 3-4 Aspartate Aminotransferase Increased
- Grade 3-4 Hepatic Enzyme Increases
- Injection Site Sciatica
- Injection Site Neuropathic Pain
Key clinical trials
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients (PHASE3)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy. (PHASE3)
- Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment (PHASE2)
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer (PHASE2)
- ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Faslodex CI brief — competitive landscape report
- Faslodex updates RSS · CI watch RSS
- Translational Oncology Research International portfolio CI